Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1985 Aug;20(1):23–28. doi: 10.1007/BF00199769

A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes

Staffan Paulie 1,✉, Barbro Ehlin-Henriksson 2, Håkan Mellstedt 3, Hannu Koho 1, Hedi Ben-Aissa 1, Peter Perlmann 1
PMCID: PMC11038404  PMID: 2998589

Abstract

We have previously described the derivation of a monoclonal antibody, S2C6, to a novel 50 Kdalton antigen associated with human urinary bladder carcinoma. No reactions were obtained with carcinomas of unrelated origin or with normal urothelial cells. However, the antibody also reacted with a similar antigen on some cell lines of B lymphocyte origin. Using large panels of target cells we have now shown that this reactivity was entirely restricted to cells of the B lineage within the haematopoietic system. As opposed to its apparent restriction to malignant cells of the urothelium, the S2C6 antigen was expressed by normal B lymphocytes as well as by many malignant B cells (chronic lymphocytic leukaemia, hairy cell leukaemia and immunocytoma). Pre-B cells derived from acute lymphocytic leukaemia and plasma cells from multiple myeloma lacked the antigen. Expression was significantly enhanced on cultured B cells from Burkitt lymphomas and on Epstein-Barr virus-transformed lymphoblastoid cell lines including those of the pre-B phenotype derived from fetal bone marrow. As judged from the molecular size and the distribution pattern displayed by the S2C6 antigen it appears to be distinct from other B cell antigens previously described. A possible relation of the S2C6 antigen to a receptor for B cell growth factors is discussed.

Keywords: Multiple Myeloma, Chronic Lymphocytic Leukaemia, Lymphocytic Leukaemia, Lymphoblastoid Cell Line, Urothelial Cell

References

  • 1.Edwards PAW, Smith CM, Neville AM, Hare MJ. A human-human hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemic-derived line. Eur J Immunol. 1982;12:641. doi: 10.1002/eji.1830120804. [DOI] [PubMed] [Google Scholar]
  • 2.Ehlin-Henriksson B, Klein G. Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationship between antigen expression and type of chromosomal translocation. Int J Cancer. 1984;33:459. doi: 10.1002/ijc.2910330407. [DOI] [PubMed] [Google Scholar]
  • 3.Ehlin-Henriksson B, Clark EA, Jønsson V, Klein G. Studies on the B lymphoblast antigen No. 1 (BB-1) on a series of Burkitt lymphoma lines differing in the expression of the EBV/C3 receptor complex. J Immunol. 1983;130:2448. [PubMed] [Google Scholar]
  • 4.Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA. 1984;81:4510. doi: 10.1073/pnas.81.14.4510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Heldin CH, Westermark B. Growth factors: Mechanism of action and relation to oncogenes. Cell. 1984;37:9. doi: 10.1016/0092-8674(84)90296-4. [DOI] [PubMed] [Google Scholar]
  • 6.Hellström KE, Hellström I, Brown JP. Monoclonal antibodies to melanoma-associated antigens. In: Wright GL, Jr (ed) Monoclonal antibodies and cancer. Marcel Dekker, Inc., New York (in press)
  • 7.Indiveri F, Ng AK, Russo C, Quaranta V, Pellegrino MA, Ferrone S. Isolation of Ia like antigen-bearing cells from human peripheral lymphocytes through the use of a monoclonal antibody to framework determinants of Ia like antigen. J Immunol Methods. 1980;39:343. doi: 10.1016/0022-1759(80)90234-3. [DOI] [PubMed] [Google Scholar]
  • 8.Jondal M, Holm G, Wigzell H. Surface markers on T and B lymphocytes. I. A large population of lymphocytes forming non-immune rosettes with sheep red blood cells. J Exp Med. 1972;136:207. doi: 10.1084/jem.136.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Klein G, Yefenof E, Falk K, Westman A. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV-receptor/complement receptor complex in a series of sublines derived from the same original Burkitt lymphoma. Int J Cancer. 1978;21:552. doi: 10.1002/ijc.2910210504. [DOI] [PubMed] [Google Scholar]
  • 10.Knowles DM, II, Tolidjian B, Marboe CC, Halper JP, Azzo W, Wang CY. A new human B-lymphocyte surface antigen (BL2) detectable by a hybridoma monoclonal antibody: Distribution on benign and malignant lymphoid cells. Blood. 1983;62:191. [PubMed] [Google Scholar]
  • 11.Koho H, Paulie S, Ben-Aissa H, Jonsdottir I, Hansson Y, Lundblad ML, Perlmann P. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence. Cancer Immunol Immunother. 1984;17:165. doi: 10.1007/BF00205481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Korsmeyer SJ, Arnold A, Bakhishi JV, Ravetch JV, Siebenlist U, Heiter PA, Sharrow SO, LeBien TW, Kersey JH, Poplack DG, Leder P, Waldman TA. Immunoglobulin gene rearrangements and cell surface antigen expression in aucte lymphoblastic leukemias of T and B cell precursor origins. J Clin Invest. 1983;71:301. doi: 10.1172/JCI110770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Larson JM, Brown JP, Wright PW, Carrasquillo JA, Hellström I, Hellström KE. Imaging of melanoma with 131I labeled monoclonal antibodies. J Nucl Med. 1983;24:123. [PubMed] [Google Scholar]
  • 14.Lennehrt K. Malignant lymphomas other than Hodgkin's disease. Histology, cytology, ultrastructure, immunology. Berlin Heidelberg New York: Springer Verlag; 1978. [Google Scholar]
  • 15.Mittler RS, Talle MA, Carpenter K, Rao PE, Goldstein G. Generation and characterization of monoclonal antibodies reactive with human B lymphocytes. J Immunol. 1983;131:1754. [PubMed] [Google Scholar]
  • 16.Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman S. Characterization of a human B cell specific antigen (B2) distinct from B1. J Immunol. 1981;126:1265. [PubMed] [Google Scholar]
  • 17.Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, Schlossman S. A human B lymphocyte associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol. 1983;131:244. [PubMed] [Google Scholar]
  • 18.Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, Jensen J, Coral F, Mayer RJ, Sallan SE, Ritz J, Schlossman SF. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984;74:332. doi: 10.1172/JCI111428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Olsson L, Kaplan H. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA. 1980;77:5249. doi: 10.1073/pnas.77.9.5429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Paulie S, Koho H, Ben-Aissa H, Hansson Y, Lundblad ML, Perlmann P. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. II. Identification of the cellular target structures by immunoprecipitation and SDS-PAGE analysis. Cancer Immunol Immunother. 1984;17:173. doi: 10.1007/BF00205482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Perlmann H, Perlmann P, Pape GR, Hallden G. Purification, fractionation and assay of antibody-dependent lymphocytic effector cells (K cells) in human blood. Scand J Immunol. 1976;5(5):57. doi: 10.1111/j.1365-3083.1976.tb03856.x. [DOI] [PubMed] [Google Scholar]
  • 22.Price MR, Campbell DG, Baldwin RW. Identification of anti-human osteogenic sarcoma monoclonal-antibody-defined antigen on mitogen-stimulated peripheral blood mononuclear cells. Scand J Immunol. 1983;18:411. doi: 10.1111/j.1365-3083.1983.tb00873.x. [DOI] [PubMed] [Google Scholar]
  • 23.Raschke WC. Monoclonal antibodies to human tumor antigens. In: Sell S, Wahren B, editors. Human tumor markers. Clifton NJ, USA: Human Press Inc.; 1982. p. 1. [Google Scholar]
  • 24.Sears HF, Herlyn D, Steplewski Z, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod. 1984;3:138. [PubMed] [Google Scholar]
  • 25.Stashenko P, Nadler LM, Hardy R, Schlossman S. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678. [PubMed] [Google Scholar]
  • 26.Taylor DW, Richmond Crum S, Kramer KJ, Siddiqui WA. Alterations in the distribution and proliferative responses of Thesus monkey peripheral blood and spleen cells during malaria (Plasmodium knowlesi) infection. Infec Immun. 1980;28:502. doi: 10.1128/iai.28.2.502-507.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Thorley-Lawson DA, Schooley RT, Bhan AK, Nalder LM. Epstein Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell. 1982;30:415. doi: 10.1016/0092-8674(82)90239-2. [DOI] [PubMed] [Google Scholar]
  • 28.Yefenof E, Klein G, Jondal M, Oldstone MBA. Surface markers on human B and T lymphocytes. IX. Two color immunofluorescence studies on the association between EBV-receptors and complement receptors on the surface of lymphoid cell lines. Int J Cancer. 1976;17:693. doi: 10.1002/ijc.2910170602. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES